BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36622700)

  • 1. Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality.
    Holtan SG; Savid-Frontera C; Walton K; Eaton AA; Demorest C; Hoeschen A; Zhang L; Reid K; Kurian T; Sayegh Z; Julia E; Maakaron J; Bachanova V; Jurdi NE; MacMillan ML; Weisdorf DJ; Felices M; Miller JS; Blazar BR; Davila ML; Betts BC
    Clin Cancer Res; 2023 Mar; 29(6):1114-1124. PubMed ID: 36622700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease.
    Shrestha B; Walton K; Reff J; Sagatys EM; Tu N; Boucher J; Li G; Ghafoor T; Felices M; Miller JS; Pidala J; Blazar BR; Anasetti C; Betts BC; Davila ML
    J Clin Invest; 2020 Sep; 130(9):4652-4662. PubMed ID: 32437331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation.
    Saberian C; Abdel-Wahab N; Abudayyeh A; Rafei H; Joseph J; Rondon G; Whited L; Gruschkus S; Fa'ak F; Daher M; Knape C; Safa H; Shoukier M; Suarez-Almazor ME; Marcotulli M; Ludford K; Gulbis AM; Konopleva M; Ohanian M; Ravandi F; Garcia-Manero G; Oran B; Popat UR; Mehta R; Alousi AM; Daver N; Champlin R; Diab A; Al-Atrash G
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.
    Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P
    Front Immunol; 2021; 12():605766. PubMed ID: 34025637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Modulation Properties of Zoledronic Acid on TcRγδ T-Lymphocytes After TcRαβ/CD19-Depleted Haploidentical Stem Cell Transplantation: An analysis on 46 Pediatric Patients Affected by Acute Leukemia.
    Merli P; Algeri M; Galaverna F; Milano GM; Bertaina V; Biagini S; Girolami E; Palumbo G; Sinibaldi M; Becilli M; Leone G; Boccieri E; Grapulin L; Gaspari S; Airoldi I; Strocchio L; Pagliara D; Locatelli F
    Front Immunol; 2020; 11():699. PubMed ID: 32477328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric Antigen Receptor T Cell Therapy followed by Unrelated Cord Blood Transplantation for the Treatment of Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia in Children and Young Adults: Superior Survival but Relatively High Post-Transplantation Relapse.
    Sun G; Tang B; Wan X; Yao W; Song K; Tu M; Geng L; Qiang P; Wu Y; Zhu L; Wu Y; Liu H; Zhu X; Sun Z
    Transplant Cell Ther; 2022 Feb; 28(2):71.e1-71.e8. PubMed ID: 34839013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
    Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
    J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning.
    Weisdorf D; Zhang MJ; Arora M; Horowitz MM; Rizzo JD; Eapen M
    Biol Blood Marrow Transplant; 2012 Nov; 18(11):1727-33. PubMed ID: 22766220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimized therapeutic strategy for patients with refractory or relapsed acute myeloid leukemia: long-term clinical outcomes and health-related quality of life assessment.
    Yan CH; Wang Y; Sun YQ; Cheng YF; Mo XD; Wang FR; Chen YH; Zhang YY; Han TT; Chen H; Xu LP; Zhang XH; Liu KY; Huang XJ
    Cancer Commun (Lond); 2022 Dec; 42(12):1387-1402. PubMed ID: 36274263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
    Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
    Jiang YL; Li Q; Pu YD; Jiang YY; Yuan T; Deng Q; Li YM; Han MZ; Zhai WH
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):495-501. PubMed ID: 32654464
    [No Abstract]   [Full Text] [Related]  

  • 13. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma.
    Fried S; Shouval R; Walji M; Flynn JR; Yerushalmi R; Shem-Tov N; Danylesko I; Tomas AA; Fein JA; Devlin SM; Sauter CS; Shah GL; Kedmi M; Jacoby E; Shargian L; Raanani P; Yeshurun M; Perales MA; Nagler A; Avigdor A; Shimoni A
    Transplant Cell Ther; 2023 Feb; 29(2):99-107. PubMed ID: 36343892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
    Cui Q; Qian C; Xu N; Kang L; Dai H; Cui W; Song B; Yin J; Li Z; Zhu X; Qu C; Liu T; Shen W; Zhu M; Yu L; Wu D; Tang X
    J Hematol Oncol; 2021 May; 14(1):82. PubMed ID: 34034795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
    Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV
    Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.
    Mushtaq MU; Shahzad M; Chaudhary SG; Luder M; Ahmed N; Abdelhakim H; Bansal R; Balusu R; DeJarnette S; Divine C; Kribs R; Shune L; Singh AK; Ganguly S; Abhyankar SH; McGuirk JP
    Transplant Cell Ther; 2021 Sep; 27(9):796.e1-796.e7. PubMed ID: 34256172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Donor Age on Allogeneic Hematopoietic Cell Transplantation Outcomes in Older Adults with Acute Myeloid Leukemia.
    Abid MB; Estrada-Merly N; Zhang MJ; Chen K; Allan D; Bredeson C; Sabloff M; Guru Murthy GS; Badar T; Hashmi S; Aljurf M; Litzow MR; Kebriaei P; Hourigan CS; Saber W
    Transplant Cell Ther; 2023 Sep; 29(9):578.e1-578.e9. PubMed ID: 37406882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and Relapse Prediction Model of Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Acute Leukemia].
    Wang XN; Zhang Y; Liu XW; Ren J; Zhao J; He PC
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):696-702. PubMed ID: 34105459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.